Travere Therapeutics delivered a strong performance in Q4 2024, with total revenue reaching $74.787 million, significantly up from the previous year. The company's net product sales, particularly from FILSPARI, were a key driver of this growth. Despite an operating loss, the company maintained a healthy cash position and is advancing its key programs, including the sNDA submission for FILSPARI in FSGS and the restart of enrollment for pegtibatinase.
Net product sales for Q4 2024 reached $73.546 million, a substantial increase from $39.916 million in Q4 2023.
FILSPARI net product sales alone contributed $49.644 million in Q4 2024, demonstrating strong commercial launch success.
The company reported a net loss of $60.264 million for Q4 2024, an improvement from a $90.173 million net loss in Q4 2023.
Cash, cash equivalents, and marketable securities stood at $370.7 million as of December 31, 2024, including $134.7 million from a common stock offering.
Travere Therapeutics is focused on advancing FILSPARI for FSGS, optimizing pegtibatinase manufacturing, and restarting its pivotal program, while also anticipating milestones from its IgAN programs and collaborations.
Analyze how earnings announcements historically affect stock price performance